A Phase 1/2 interventional study of REGN13089-M404-M2980 in Advanced Solid Tumors, sponsored by Regeneron Pharmaceuticals. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,143 studies in Carcinoma, Renal Cell with a site in United States — 155 open to participants now, 279 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.
Among the 1,143 studies in Carcinoma, Renal Cell with a site in United States, this one is the 94th largest by planned enrollment of the 1,009 interventional ones that give a count, is one of 44 that started in 2026, is one of 147 in phase 1/2, reaches primary completion later than 259 of the 277 other live ones, and was the 1,140th registered.
2,041 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.
Browse Carcinoma, Renal Cell studies →155 of the 1,143 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
University of Oklahoma · Sites in United States
Ages 18–100 · Men only
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 489 · Phase 2 530 · Phase 3 74 · Phase 4 10
First in 1990; this study’s year is marked. 44 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 320 is above the median of 43 across 1,567 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 40 across the 1,009 interventional studies, 100 across the 87 observational. Of the 793 that completed or were terminated, 336 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
468 of 1,143 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 4 studies filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
97 of the studies in Carcinoma, Renal Cell with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05678673Phase 3ExelixisStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | 2026-12-15 |
| NCT03592472Phase 3Xynomic Pharmaceuticals, Inc.A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | 2026-12-30 |
| NCT03873402Phase 3Bristol-Myers SquibbA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | 2027-03-11 |
| NCT05863351Phase 3ECOG-ACRIN Cancer Research GroupFocused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study | 2027-08-31 |
Add all 97 to your calendar (.ics) → With an account.
Among the 1,143 studies in Carcinoma, Renal Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial transition factor (MET) on the surface of their cells than usual. The study drug works by binding to MET on tumor cells and delivering chemotherapy directly into those cells. This may stop growth of the cancer cells and kill only the cancer cells and not the other normal tissues in your body. However, some of the chemotherapy may still affect the normal cells and side effects can still occur.
The study is looking at:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined inclusion/ exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: REGN13089-M404-M2980
Drug: REGN13089-M404-M2980
Administered per the protocol
Occurrence of dose-limiting toxicities (DLTs)
Part 1 (Dose Escalation)
Time frame: Up to 21 days
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Part 1 (Dose Escalation)
Time frame: Up to approximately 5 years
Occurrence of Serious Adverse Events (SAEs)
Part 1 (Dose Escalation)
Time frame: Up to approximately 5 years
Occurrence of adverse event of special interests (AESIs)
Part 1 (Dose Escalation)
Time frame: Up to approximately 5 years
Objective response (OR) (investigator assessed) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Part 2 (Dose Expansion)
Time frame: Up to approximately 5 years
Objective response (investigator assessed) per RECIST 1.1
Part 1 (Dose Escalation)
Time frame: Up to approximately 5 years
Concentrations of ADC
Part 1 (Dose Escalation) and Part 2 (Dose Expansion)
Time frame: Up to approximately 5 years
Concentrations of total antibody
Part 1 (Dose Escalation) and Part 2 (Dose Expansion)
Time frame: Up to approximately 5 years
Concentrations of payload (ProDXd and DXd)
Part 1 (Dose Escalation) and Part 2 (Dose Expansion)
Time frame: Up to approximately 5 years
Occurrence of Anti-Drug Antibodies (ADA) against REGN13089-M404-M2980
Part 1 (Dose Escalation) and Part 2 (Dose Expansion)
Time frame: Up to approximately 5 years
Magnitude of ADA against REGN13089-M404-M2980
Part 1 (Dose Escalation) and Part 2 (Dose Expansion)
Time frame: Up to approximately 5 years
Duration of response per RECIST 1.1
Part 2 (Dose Expansion)
Time frame: Up to approximately 5 years
Time to response per RECIST 1.1
Part 2 (Dose Expansion)
Time frame: Up to approximately 5 years
Progression-free survival per RECIST 1.1
Part 2 (Dose Expansion)
Time frame: Up to approximately 5 years
Overall survival
Part 2 (Dose Expansion)
Time frame: Up to approximately 5 years
Occurrence of TEAEs considered clinically significant
Part 2 (Dose Expansion)
Time frame: Up to approximately 5 years
Laboratory abnormalities considered clinically significant
Part 2 (Dose Expansion)
Time frame: Up to approximately 5 years
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Mar 2031, 52 months after the start.
Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 52 months is below that.
Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.
Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.